Free Trial

RAPT Therapeutics (RAPT) Competitors

$3.43
-0.05 (-1.44%)
(As of 07/12/2024 ET)

RAPT vs. ANNX, ERAS, HRTX, OCS, ESPR, FULC, CMPS, TBPH, IGMS, and LYEL

Should you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Annexon (ANNX), Erasca (ERAS), Heron Therapeutics (HRTX), Oculis (OCS), Esperion Therapeutics (ESPR), Fulcrum Therapeutics (FULC), COMPASS Pathways (CMPS), Theravance Biopharma (TBPH), IGM Biosciences (IGMS), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical preparations" industry.

RAPT Therapeutics vs.

RAPT Therapeutics (NASDAQ:RAPT) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

RAPT Therapeutics received 41 more outperform votes than Annexon when rated by MarketBeat users. However, 74.60% of users gave Annexon an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.

CompanyUnderperformOutperform
RAPT TherapeuticsOutperform Votes
88
66.17%
Underperform Votes
45
33.83%
AnnexonOutperform Votes
47
74.60%
Underperform Votes
16
25.40%

RAPT Therapeutics currently has a consensus price target of $24.67, suggesting a potential upside of 619.14%. Annexon has a consensus price target of $15.33, suggesting a potential upside of 152.19%. Given RAPT Therapeutics' higher probable upside, analysts plainly believe RAPT Therapeutics is more favorable than Annexon.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RAPT Therapeutics
0 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.31
Annexon
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Annexon's return on equity of -56.52% beat RAPT Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
RAPT TherapeuticsN/A -72.61% -62.99%
Annexon N/A -56.52%-46.50%

99.1% of RAPT Therapeutics shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by company insiders. Comparatively, 12.7% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

RAPT Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RAPT Therapeutics$1.53M78.24-$116.80M-$3.07-1.12
AnnexonN/AN/A-$134.24M-$1.47-4.14

RAPT Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

In the previous week, Annexon had 4 more articles in the media than RAPT Therapeutics. MarketBeat recorded 6 mentions for Annexon and 2 mentions for RAPT Therapeutics. RAPT Therapeutics' average media sentiment score of 1.45 beat Annexon's score of 0.54 indicating that RAPT Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RAPT Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Annexon
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Annexon beats RAPT Therapeutics on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RAPT vs. The Competition

MetricRAPT TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$119.71M$7.24B$5.31B$8.66B
Dividend YieldN/A2.75%2.83%4.05%
P/E Ratio-1.128.6699.4513.87
Price / Sales78.24274.392,167.3079.19
Price / CashN/A33.3335.2432.70
Price / Book0.805.844.904.46
Net Income-$116.80M$146.83M$110.78M$215.59M
7 Day Performance22.50%10.50%6.14%5.37%
1 Month Performance-1.44%4.69%4.31%3.37%
1 Year Performance-83.76%-0.56%5.54%0.94%

RAPT Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANNX
Annexon
1.8218 of 5 stars
1.82 / 5 stars
$5.04
-0.2%
$15.33
+204.2%
+58.3%$466.69MN/A-3.4370Short Interest ↑
News Coverage
ERAS
Erasca
2.0643 of 5 stars
2.06 / 5 stars
$2.68
-1.1%
$6.00
+123.9%
+6.8%$464.61MN/A-3.19129Short Interest ↑
News Coverage
High Trading Volume
HRTX
Heron Therapeutics
3.4198 of 5 stars
3.42 / 5 stars
$3.04
+3.4%
$6.00
+97.4%
+141.8%$457.98M$127.04M-4.98126Short Interest ↑
News Coverage
OCS
Oculis
2.2713 of 5 stars
2.27 / 5 stars
$11.20
+1.7%
$30.17
+169.3%
-6.0%$453.60M$980,000.00-6.2936Positive News
Gap Down
ESPR
Esperion Therapeutics
4.4332 of 5 stars
4.43 / 5 stars
$2.36
-4.5%
$8.83
+274.3%
+51.2%$447.13M$116.33M-2.38240Short Interest ↓
Positive News
FULC
Fulcrum Therapeutics
1.3712 of 5 stars
1.37 / 5 stars
$7.09
+8.6%
$15.57
+119.6%
+115.9%$440.67M$2.51M-4.4376Analyst Forecast
Short Interest ↑
CMPS
COMPASS Pathways
1.8652 of 5 stars
1.87 / 5 stars
$6.60
+4.9%
$47.40
+618.2%
-23.1%$430.12MN/A-2.78186Positive News
TBPH
Theravance Biopharma
2.3767 of 5 stars
2.38 / 5 stars
$8.82
-1.1%
$20.50
+132.4%
-5.5%$428.92M$57.42M-10.26359Analyst Upgrade
News Coverage
Positive News
IGMS
IGM Biosciences
3.6054 of 5 stars
3.61 / 5 stars
$7.01
-5.1%
$17.89
+155.2%
-7.2%$413.76M$2.11M-1.63224News Coverage
Positive News
Gap Up
LYEL
Lyell Immunopharma
2.5867 of 5 stars
2.59 / 5 stars
$1.58
-1.3%
$4.00
+153.2%
-44.8%$402.81M$130,000.00-1.76224Short Interest ↓
Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:RAPT) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners